We recently published a list of Top 10 Insider Sales Last Month. In this article, we are going to take a look at where ...

Wells Fargo raised the firm’s price target on Cencora (COR) to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is ...

We recently published a list of 10 Stocks With At Least $30 Million In Insider Sales Recently. In this article, we are going ...

Proficio Capital Partners LLC bought a new position in Cencora, Inc. (NYSE:COR – Free Report) in the 4th quarter, according ...

Cencora (NYSE:COR) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging population. Learn more on COR stock here.

Cencora (NYSE:COR) has made headlines with its announcement on March 10, 2025, detailing plans for strategic acquisitions and investments in technology infrastructure, aiming to drive future growth.

This medical supplies distributor raised its 2025 earnings outlook on Monday. Cencora stock is near a buy point of a newly formed base. Cencora (NYSE:COR) has made headlines with its announcement ...

Shares of Cencora Inc. COR slid 2.56% to $254.00 Wednesday, on what proved to be an all-around mixed trading session for the ...

With the capital infusion, Lumata will look to grow its headcount from more than 200 to about 400 to meet surging demand.